English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Canine non‐infectious, inflammatory meningoencephalomyelitis is termed meningoencephalomyelitis of unknown etiology ( MUE ) and may affect dogs of any age, breed or gender. Treatment with immunosuppressive medication has been widely reported, however no prospective clinical trials with a standard glucocorticoid monotherapy are available. The objectives were to compare the cerebrospinal fluid ( CSF ) analysis at diagnosis and after treatment with a standard glucocorticoid ( GC ) dose and to determine the survival time in dogs with  MUE . We hypothesized that abnormal  CSF  findings would normalize in dogs with  MUE , and survival time would be longer than previously reported for glucocortocoid therapy alone. Inclusion criteria were: (1) normal minimum database, (2) no  GC  use within 5 days, (3) magnetic resonance imaging performed, (4) negative infectious disease titres, and (5) abnormal  CSF  analysis. All dogs received  GC  therapy at 1 mg/kg  per os  q 12 h. Responders had normal  CSF  analysis at 1 month. Sixteen dogs met the inclusion criteria. Median total nucleated cell count ( TNCC ) and protein concentration at time of diagnosis were 39 cells/ μ L (0–1400 cells/ μ L), and 49 mg/ dL  (25–293 mg/ dL ), respectively. Median  TNCC  and protein concentration at 1 month were 1 cell/ μ L (0–120 cells/ μ L), and 24 mg/dL (13–175 mg/ dL ), respectively. Seven of 16 dogs (44%) were responders. There was no significant difference in survival between the  CSF  responders and  CSF  non‐responders ( P  = 0.85). Overall median survival was 602 days (45–654 days). This study supports using  GC  therapy in dogs with MUE.

Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogs